The occlusive-type pulsatile extracorporeal blood pump (T-PLS, Seoul National University, Seoul, Korea) received the Communauté Européenne mark of the European Directives (2003) and Korea Food and Drug Administration approval (2004) for short-term application as an extracorporeal life support system. The pump system was recently upgraded in the ameliorated actuator head for reducing hemolysis, rather than in the existing actuator head. In this study, the hemolytic performance of the new pump system (assessed as the degree of occlusiveness of the blood sac) was compared with the existing one. A roller pump, the Stockert S3 (Stockert Instrumente GmbH, Munchen, Germany), was selected as a control device. Five tests were conducted for each pump, with each of these tests lasting for 6 h. A pump flow of 3 L/min with 50 beats per minute was included in the hemolytic test conditions. The lowest hemolytic results were obtained by the new pump system yielding a normalized index of hemolysis of less than 0.005 g/100 L, and this result was one-fourth that of the roller pump, Stockert S3.